Siemens and GE have each achieved milestones in IT, landing key customers for their integrated RIS/PACS products. Bethesda Healthcare System in Boynton Beach, FL, became the first healthcare provider to implement Siemens' RIS/PACS combination. The
Siemens and GE have each achieved milestones in IT, landing key customers for their integrated RIS/PACS products. Bethesda Healthcare System in Boynton Beach, FL, became the first healthcare provider to implement Siemens' RIS/PACS combination. The integrated product eliminates the need for additional electronic devices, or "brokers," to communicate between RIS and PACS. Bethesda Healthcare deployed the product in its emergency department, intensive care unit, neonatal intensive care unit, radiation oncology, women's health, and imaging services. The integrated RIS/PACS is the first product resulting from the merger of medical technology and equipment manufacturer Siemens Medical Solutions with former healthcare IT company Shared Medical Systems, now known as Siemens Medical Solutions Health Services. The new product is a combination of SHS' snewly released Novius Radiology Information System, version 26, and Siemens' Sienet PACS. Speech recognition was also added.
GE Medical Systems Information Technologies has signed a five-year agreement with Illawarra Area Health Service, which will provide the GE Centricity RIS/PACS and Centricity Computed Radiography (CR) products to the Wollongong Hospital complex in New South Wales, Australia. Wollongong is a six-hospital campus featuring a major public teaching facility and peripheral support facilities. The RIS/PACS will allow clinicians to electronically access patient images and medical information at a single workstation; the CR component will feed digital x-ray images into the RIS/PACS. The agreement marks the first integrated Centricity RIS/PACS in Australia/New Zealand and Asia, and the largest multiple-site implementation of the technology, covering approximately 161 miles.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.